

## **The genetic overlap between mood disorders and cardio-metabolic diseases: A systematic review of genome wide and candidate gene studies**

Azmeraw T. Amare<sup>1\*</sup>, Klaus Oliver Schubert<sup>1</sup>, Sarah Cohen-Woods<sup>2</sup>, Bernhard T. Baune<sup>1</sup>

\*Correspondence to Azmeraw T. Amare [azmerawtayelgn3@gmail.com](mailto:azmerawtayelgn3@gmail.com)

<sup>1</sup>Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, SA, Australia

<sup>2</sup>School of Psychology, Faculty of Social and Behavioural Sciences, Flinders University, Adelaide, SA, Australia

## ABSTRACT

Meta-analyses of genome-wide association studies (meta-GWAS) and candidate gene studies have identified genetic variants associated with cardiovascular diseases, metabolic diseases, and mood disorders. Although previous efforts were successful for individual disease conditions (single disease), limited information exists on shared genetic risk between these disorders. This article presents a detailed review and analysis of cardio-metabolic diseases risk (CMD-R) genes that are also associated with mood disorders. Firstly, we reviewed meta-GWA studies published until January 2016, for the diseases "type 2 diabetes, coronary artery disease, hypertension" and/or for the risk factors "blood pressure, obesity, plasma lipid levels, insulin and glucose related traits". We then searched the literature for published associations of these CMD-R genes with mood disorders. We considered studies that reported a significant association of at least one of the CMD-R genes and "depressive disorder" OR "depressive symptoms" OR "bipolar disorder" OR "lithium treatment", OR "serotonin reuptake inhibitors treatment". Our review revealed 24 potential pleiotropic genes that are likely to be shared between mood disorders and CMD-Rs. These genes include *MTHFR*, *CACNA1D*, *CACNB2*, *GNAS*, *ADRB1*, *NCAN*, *REST*, *FTO*, *POMC*, *BDNF*, *CREB*, *ITIH4*, *LEP*, *GSK3B*, *SLC18A1*, *TLR4*, *PPP1R1B*, *APOE*, *CRY2*, *HTR1A*, *ADRA2A*, *TCF7L2*, *MTNR1B*, and *IGF1*. A pathway analysis of these genes revealed significant pathways: corticotrophin-releasing hormone signaling, AMPK signaling, cAMP-mediated or G-protein coupled receptor signaling, axonal guidance signaling, serotonin and dopamine receptors signaling, dopamine-DARPP32 feedback in cAMP signaling, circadian rhythm signaling and leptin signaling. Our findings provide insights in to the shared biological mechanisms of mood disorders and cardio-metabolic diseases.

**Keywords:** Depression, bipolar disorder, pleiotropy, pathway, cardio-metabolic diseases

## **INTRODUCTION**

Major depressive disorder (MDD), bipolar disorder (BPD), coronary artery diseases, type 2 diabetes and hypertension are amongst the major causes of disability, morbidity and mortality worldwide (1, 2). While each of these conditions independently represent a major burden facing the health-care systems (1-3), their co-occurrence (co-morbidity) aggravates the situation and represents a challenge in psychosomatic medicine. Epidemiologically, MDD and BPD are bi-directionally associated with cardio-metabolic diseases (4, 5). One explanation for these relationships could be the presence of pleiotropic (common) genes and shared biological pathways that function as a hub encoding for proteins connecting the disorders. Potential common biological mechanisms underlying mood disorders and cardio-metabolic disease comorbidity have been proposed, including altered circadian rhythms (6), abnormal hypothalamic-pituitary-adrenal axis (HPA axis) function (7), imbalanced neurotransmitters (8), and inflammation (5). However, the molecular drivers of these commonly affected mechanisms remain poorly understood.

### **The genetics of mood disorders and cardio-metabolic diseases**


Major depression, bipolar disorder and cardio-metabolic diseases are highly heritable and caused by a combination of genetic and environmental factors. Genetic factors contribute to 31-42% in MDD (9), 59% - 85% in BPD (10, 11), 30-60% in coronary artery diseases (12), 26-69% in type 2 diabetes (13, 14), 24-37% in blood pressure (15), 40–70% in obesity (16), and 58-66% in serum lipids level (17). Moreover, twin studies have revealed high genetic co-heritabilities (genetic correlations) between mood disorders and the different cardio-metabolic disorders suggesting the influence of pleiotropic genes and shared biological pathways among them. For

instance, the genetic correlation of depression with hypertension is estimated to be 19%, and between depression and heart disease is about 42% (18). The genetic correlation of depressive symptoms with plasma lipids level ranges from 10% to 31% (19), and 12% of the genetic component for depression is shared with obesity (20).

In the last decade, substantial amounts of univariate (single disease) meta-GWA studies and candidate gene studies have been published. Indeed, the meta-GWA studies and candidate gene studies have successfully identified a considerable list of candidate genes for major depressive disorder (21, 22), bipolar disorder (23), coronary artery diseases (24), type 2 diabetes (25), hypertension (26), obesity (27), plasma lipids level (28), insulin and glucose traits (25, 29, 30), and blood pressure (26, 31).

Despite the potential significance of studying pleiotropic genes and shared biological pathways, previous meta-GWAS and candidate gene studies were entirely focused on a single phenotype approach (single disease). A recent analysis of SNPs and genes from the NHGRI GWAS catalogue (32) has showed as 16.9% of the genes and 4.6% of the SNPs have pleiotropic effects on complex diseases (33). Considering such evidence, we hypothesized that common genetic signatures and biological pathways mediate the mood disorders to cardio-metabolic diseases relationship. Additionally, these genes and their signalling pathways can influence the response to treatments in mood disorder patients (figure 1). In this review, we systematically investigated the CMD-R genes that are possibly associated with mood disorders susceptibility, and with treatment response to MDD and BPD. We performed pathway and gene network analyses of these genes to provide additional insights in to the common pathways and biological mechanisms

regulating mood disorders and the CMD-Rs. Understanding of these common pathways may provide new insights and novel ways for the diagnosis and treatment of comorbid cardio-metabolic and mood disorders.



**Figure 1.** Schematic model of the potential pleiotropic effects of a shared gene locus that is associated with mood disorders and cardio-metabolic diseases. The red bold lines represent the pleiotropic effect of a genetic locus on CMD-Rs, MDD, BPD and treatment response in MDD and BPD. The bidirectional arrows indicate bidirectional relationships. MDD: Major depressive disorder, BPD: Bipolar disorder, CMD-Rs: cardio-metabolic diseases and risk factors.

## **METHODS AND MATERIALS**

### **SEARCH STRATEGY**

#### **Step 1: Identification of published candidate genes for cardio-metabolic diseases**

We carried out a systematic search of candidate genes for the cardio-metabolic diseases and/or associated risk factors. The National Human Genome Research Institute (NHGRI) GWAS catalogue (32), Westra et al., 2013 (34) and Multiple Tissue Human Expression Resource (MuTHER)(35) databases were used to identify the CMD-R genes. We reviewed meta-GWA study papers published until January 2016 for the diseases "type 2 diabetes" OR "coronary artery disease" OR "hypertension" and (or) for the risk factors "blood pressure" OR "obesity or body mass index (BMI)" OR "plasma lipid levels (high-density lipoprotein, low-density lipoprotein, triglycerides, total cholesterol)" OR "insulin and glucose related traits (fasting glucose, fasting insulin, fasting proinsulin, insulin resistance-HOMA-IR), beta cell function-HOMA- $\beta$  and glycated haemoglobinA1C-HbA1C)".

GWAS significant SNPs information (lead SNPs, reported genes, author (s), PubMed ID, date of publication, journal, discovery and replication sample sizes) was downloaded from the GWAS catalogue database. Additional information about the effect of the lead SNPs on nearby gene expression (cis-eQTLs) was collected from their respective publications. For the SNPs with no cis-eQTL information in their respective publications, we performed expression quantitative trait loci (cis-eQTL) analysis to verify the functional relationship between the reported genes and the lead SNPs using two publicly available databases: Westra et al., 2013 (34), and MuTHER (35). A CMD-R gene was considered as a candidate gene if, 1) it was nearby to the lead SNP and its expression was influenced by the lead SNP (cis-eQTL); or 2) the genes were biologically well known to influence at least one of the CMD-

All rights reserved. No reuse allowed without permission.  
Rs. We took the identified CMD-R genes forward for the second literature review, as described below.

## **Step 2: Exploration of the role of cardio-metabolic genes in mood disorders**

In the second systematic review, we conducted a literature search in PubMed (MEDLINE database) for any genome wide association, candidate gene, or gene expression analysis study published in the fields of mood disorders and mood disorders pharmacogenetics until January 2016. We considered studies that reported at least one of the CMD-R genes for "depressive disorder" OR "depressive symptoms" OR "bipolar disorder" OR "mood disorder" OR "lithium treatment", OR "Selective Serotonin Reuptake Inhibitors (SSRIs) treatment".

## **BIOLOGICAL PATHWAY AND NETWORK ANALYSIS**

The potential pleiotropic genes were further explored to identify the most enriched canonical pathways and visualize gene networks using QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)). For the analysis, all the twenty-four potential pleiotropic genes were entered into the software. IPA compares the proportion of input genes mapping to a biological pathway to the reference genes in the Ingenuity databases. The significance of the overrepresented canonical pathways were determined using the right-tailed Fisher's exact test. After correction for multiple testing, significance levels were expressed as the IPA p-value. A gene networks that connects the input genes with MDD, BPD and the cardio-metabolic disorders was also generated.




## RESULTS

### Characteristics of meta-GWA studies for the cardio-metabolic disorders

The literature search in the GWAS catalogue yielded 153 meta-GWA studies for the CMD-Rs: 38 studies for type 2 diabetes, 17 studies for coronary artery disease, 15 studies for hypertension and blood pressure, 26 studies for obesity (BMI), 37 studies for lipids and 20 studies for glucose and insulin traits (figure 2). As shown in figure 2, the meta-GWA studies reported 1047 lead SNPs and 682 nearby genes. Of these, 123 genes were biologically relevant to the cardio-metabolic diseases and associated risk factors. These genes were reviewed for their association with mood disorders and pharmacogenetics of mood disorders. Twenty-four of the 123 genes have been implicated in mood disorders and/or pharmacogenetics of mood disorders; and we named these genes the Cardio-Metabolic Mood disorders hub (CMMDh) genes.

Table-1 summarizes the 24 CMMDh genes and specific genetic variants across mood disorders and cardio-metabolic diseases. These genes are *MTHFR*, *CACNA1D*, *CACNB2*, *GNAS*, *ADRB1*, *NCAN*, *REST*, *FTO*, *POMC*, *BDNF*, *CREB*, *ITIH4*, *LEP*, *GSK3B*, *SLC18A1*, *TLR4*, *PPP1R1B*, *APOE*, *CRY2*, *HTR1A*, *ADRA2A*, *TCF7L2*, *MTNR1B*, and *IGF1* (for further details see table 1). These genes were over-represented in the following biological pathways; corticotrophin-releasing hormone signaling (*BDNF*, *CREB1*, *GNAS*, *POMC*); AMPK signaling (*ADRA2A*, *ADRB1*, *CREB1*, *GNAS*, *LEP*); cAMP-mediated and G-protein coupled receptor signaling (*ADRA2A*, *ADRB1*, *CREB1*, *GNAS*, *HTR1A*); axonal guidance signaling (*BDNF*, *GNAS*, *GSK3B*, *IGF1*); serotonin and dopamine receptors signaling (*GNAS*, *HTR1A*, *SLC18A1*, *PPP1R1B*); dopamine-DARPP32 feedback in cAMP (*PPP1R1B*, *CACNA1D*, *CREB1*, *GNAS*); leptin signaling (*GNAS*, *LEP*, *POMC*) and the circadian rhythm signaling(*CRY2*,*CREB1*) (table 2).



**Figure 2:** The flow chart shows the stages of literature search and evaluation of candidate

pleiotropic genes for the CMD-Rs and mood disorders. CMD-R genes refers to the genes that were biologically well-known to influence at least one of the CMD-Rs or those genes nearby to the lead SNPs and their expression was influenced by the lead SNPs (cis-eQTL).

CMD-R: Cardio-metabolic diseases and associated risk factors, MuTHER: Multiple Tissue Human Expression Resource, CMMDh: Cardio-Metabolic Mood Disorders hub genes, Cis-eQTL: Cis (nearby) gene expression quantitative trait loci.

**Table 1:** An overview of the 24 CMMDh genes shared between mood disorders and the cardio-metabolic diseases

Pleiotropic genes	Function of the coded protein	Polymorphisms associated with	
		Cardio-metabolic disorders (lead SNP)	Mood disorders (description)
<i>MTHFR</i>	Part of the process to build amino-acids and to form vitamin folate	<u>Blood pressure</u> rs17367504-G/A (36)	The common <i>MTHFR</i> C677T was associated with depression (37), and BPD (38). <i>MTHFR</i> gene polymorphisms interaction with childhood trauma increases the risk for depression (39).
<i>CACNAID</i>	Mediates the entry of calcium ions into cells	<u>Blood pressure and hypertension</u> rs9810888-G/T (26)	Rare variants in the calcium channel genes ( <i>CACNAIB</i> , <i>CACNAIC</i> , <i>CACNAID</i> , <i>CACNG2</i> ) contribute to BPD (40) and may influence treatment response to lithium (41).
<i>CACNB2</i>	Mediates the entry of calcium ions into cells	<u>Blood pressure</u> rs4373814-G/C (31) rs12258967-G/C (36) rs11014166-A/T (42)	<i>CACNB2</i> gene polymorphisms were implicated in MDD and BPD (43).
<i>GNAS</i>	Control the activity of endocrine glands through adenylate cyclase enzyme	<u>Blood pressure and hypertension</u> rs6015450-G/A (31)	SNPs in the <i>GNAS</i> gene were associated with BPD (rs6064714, rs6026565, rs35113254) (44) and may influence antidepressant treatment response (45).
<i>ADRB1</i>	Mediates the effects of epinephrine and norepinephrine	<u>Blood pressure</u> rs2782980-T/C (36)	Gly389 polymorphism of the beta-1 adrenergic receptor might lead to better response to antidepressant treatment in patients with MDD (46)

<b><i>REST</i></b>	Regulate neurogenesis	<u>Coronary artery disease</u> rs17087335-T/G (24)	Reduced expression of <i>REST</i> in MDD patients at depressive state (47), and alteration in the expression of the <i>REST</i> gene was revealed in the brain of women with MDD (48).
<b><i>LEP</i></b>	Regulate body weight	<u>Type 2 diabetes</u> rs791595-A/G (49)	SNPs in the leptin gene, decreased leptin gene expression and leptin deficiency in serum were related to antidepressant resistance (50). A significant reduction of the mRNA expression was found in the brain of MDD and suicidal patients (51).
<b><i>ADRA2A</i></b>	Regulate neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system	<u>Type 2 diabetes or fasting glucose</u> rs10885122-G/T (25)	<i>ADRA2A</i> gene polymorphisms ( <i>ADRA2A</i> -1291G-male, <i>ADRA2A</i> -1291G-female) were associated with sex-specific MDD (52), predicted antidepressant treatment outcome in MDD (53), and modified the effect of antidepressants for better improvement (54). However, they increased suicidal ideation during antidepressant treatment (55). Treatment with lithium produced an over expression of the <i>ADRA2A</i> gene in rats brain (56).
<b><i>TCF7L2</i></b>	Regulate blood glucose homeostasis	<u>Type 2 diabetes</u> rs7903146-T/C (57) <u>Fasting glucose, proinsulin, insulin levels, or insulin resistance</u> rs7903146-T/C (29)	Genome-wide association study of BPD in European Americans identifies a new risk allele (rs12772424-A/T) within the <i>TCF7L2</i> gene (58)

rs4506565-T/A (25, 30)

<b><i>HTR1A</i></b>	Receptor for serotonin	<u>Fasting insulin or insulin resistance</u> rs16891077-A/G (59)	Variants in the <i>HTR1A</i> gene (rs6295, rs878567) were related to MDD and BPD (60, 61). A significant decrease in <i>HTR1A</i> mRNA levels in the brain of patients with MDD and BPD was found(62). Other polymorphisms (5-HT1A-1019G, Gly272Asp) in this gene were associated with antidepressant treatment response in MDD (63-65) and in BPD (64). Increased DNA methylation in the promoter region of the <i>HTR1A</i> gene was also observed in patients with BPD (66).
<b><i>CRY2</i></b>	Regulates the circadian clock	<u>Fasting glucose or insulin</u> rs11605924-A/C (25, 30)	Polymorphisms in <i>CRY2</i> gene were significantly associated with MDD (67) and BPD (67, 68).
<b><i>MTNR1B</i></b>	Receptor for melatonin that participate in light-dependent functions in the retina and brain. May be involved in the neurobiological effects of melatonin	<u>Type 2 diabetes or plasma glucose level</u> rs3847554-C/T (30) rs10830962-C/G (69) rs2166706-T/C (70) rs10830963-G/C (25) rs1387153-T/C (71, 72)	Galecka et al. 2011 reported the significance of the <i>MTNR1B</i> gene polymorphism (rs4753426) for recurrent MDD (73). Additional SNP on the <i>MTNR1B</i> gene (rs794837) increased mRNA level in MDD patients (73).


<b><i>IGF1</i></b>	Involved in mediating body growth and development	<u>Fasting insulin, fasting glucose, or glucose homeostasis</u> rs35767-G/A (25), rs35747-G/A (30)	Elevated levels of IGF-I was associated with MDD and antidepressant treatment response (74). A long-term deficiency of IGF-1 in adult mice induced depressive behaviour (75). Polymorphisms in the <i>IGF1</i> gene increased BPD risk (76). An over-expression of <i>IGF1</i> gene of BPD patients who respond well for lithium treatment was also reported (77).
<b><i>FTO</i></b>	Regulates energy homeostasis, contributes to the regulation of body size and body fat accumulation	<u>Obesity</u> rs7185735-G/A (27, 78) <u>Type 2 diabetes</u> rs9936385-C/T (57) <u>HDL or triglycerides</u> rs1121980-A/G (28)	The <i>FTO</i> gene variant (rs9939609-A/T) was associated with depression (79). Other variants of the <i>FTO</i> gene were involved in the mechanism underlying the association between mood disorders and obesity(80).
<b><i>POMC</i></b>	Maintain the body's energy balance and control sodium in the body	<u>Obesity (BMI)</u> rs713586-C/T (81) rs1561288-T/C (82) rs10182181-G/A (78)	Genetic variants in this gene were involved in treatment response to SSRIs (escitalopram or mirtazapine) in MDD patients (83).
<b><i>ITIH4</i></b>	Involved in inflammatory responses	<u>Obesity (BMI)</u> rs2535633-G/C (84)	Genetic variants located in the regions of <i>ITIH1</i> , <i>ITIH3</i> , <i>ITIH4</i> genes were associated with BPD (23), and suicidal attempt in BPD patients (85).

<b><i>TLR4</i></b>	Pathogen recognition and activation of innate immunity	<u>Obesity (BMI)</u> rs1928295-T/C (27)	The mRNA levels of the <i>TLR3</i> and <i>TLR4</i> genes were increased in depressed suicidal patients (86). <i>TLR4</i> gene expression was related to severity of major depression (87).
<b><i>BDNF</i></b>	Promotes the survival of nerve cells	<u>Obesity (BMI)</u> rs2030323-C/A (27, 78) rs925946-T/G (88) rs10767664-A/T (81)	The Val66Met polymorphism was associated with depressive disorder (89), BPD (90) and suicidal behavior in depressed and BPD patients (91, 92). It was also associated with SSRIs (escitalopram) response in depressed patients (93). A significantly decreased expression of the <i>BDNF</i> gene was observed in the lymphocytes and platelets of depressed patients (94). Treatment responsive depressive patients have also shown a decreased mRNA levels of the <i>BDNF</i> gene (95).
<b><i>CREB1</i></b>	Involved in different cellular processes including the synchronization of circadian rhythmicity and the differentiation of adipose cells	<u>Obesity</u> rs17203016-G/A (27)	SNPs within this gene were associated with MDD risk in women (96) and antidepressants treatment resistance in MDD patients (97). An interaction of <i>CREB1</i> gene variants with <i>BDNF</i> variants predicted response to paroxetine (98). The <i>CREB1</i> gene variants (rs6785, rs2709370) increased BPD susceptibility (99) and other SNPs on <i>CREB1</i> were suggested for BPD and lithium response (100).
<b><i>NCAN</i></b>	Modulation of cell adhesion and migration	<u>Total cholesterol</u> rs2304130-G/A (101) <u>LDL cholesterol</u>	A SNP (rs1064395) in <i>NCAN</i> gene was found to be a risk factor for BPD in the European population (104). This SNP might resulted in a structural change of the brain cortex



		rs16996148-G/T (102) rs10401969-C/T (103) <u>Triglycerides</u> rs17216525-T/C (103) rs16996148-G/T (102)	folding (105)
<b><i>GSK3B</i></b>	Energy balance, metabolism, neuronal cell development, and body pattern formation	<u>HDL cholesterol</u> rs6805251-T/C (28)	Higher <i>GSK3B</i> activity was observed in MDD patients with severe depressive episode (106). Polymorphisms of this gene (rs334555, rs119258668, rs11927974) were implicated in MDD (107). In addition, rare variants in <i>GSK3B</i> gene increased BPD risk (108, 109). The <i>GSK3B</i> is a target gene for several mood stabilizers including lithium (110, 111).
<b><i>SLC18A1</i></b>	Accumulate and transport neurotransmitters	<u>Triglycerides</u> rs9644568-A/G (112) rs79236614-G/C (113) rs326-A/G (114)	Variations in the <i>SLC18A1</i> (rs988713, rs2279709, Thr136Ser) gene confer susceptibility to BPD (115).
<b><i>PPP1R1B</i></b>	A target for dopamine	<u>HDL cholesterol</u> rs11869286-G/C (28)	<i>DARPP-32</i> decreased in the prefrontal cortex of BPD patients (116), increased expression was also shown in BPD (117).
<b><i>APOE</i></b>	Maintaining normal levels of cholesterol	<u>HDL, LDL or total cholesterol</u> rs4420638-A/G (28) rs1160985-C/T (118) rs519113-C/G (119)	Genetic variation at the <i>APOE</i> gene contributed to depressive symptoms (120).

CMD-R: Cardio-metabolic diseases and associated risk factors; SNP: Single nucleotide polymorphism; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; BPD: bipolar disorder; MDD: Major depressive disorder



**Figure 2:** IPA-generated network of genes, as indicated by the dashed lines, shared between coronary artery diseases, hypertension, diabetes mellitus, obesity, MDD and BPD, highlighting CMMDh genes that were related to bipolar disorder (orange) and depression (red).

**Table 2:** The top canonical signaling pathways enriched for the cardio-metabolic mood disorders hub genes

Canonical pathways	Enriched genes	P-value
Corticotrophin releasing hormone	<i>BDNF, CREB1, GNAS, POMC</i>	$7.77 \times 10^{-6}$
AMPK signaling	<i>ADRA2A, ADRB1, CREB1, GNAS, LEP</i>	$1.68 \times 10^{-6}$
cAMP-mediated	<i>ADRA2A, ADRB1, CREB1, GNAS, HTR1A</i>	$4.65 \times 10^{-6}$
G-Protein coupled receptor		$9.92 \times 10^{-6}$
Dopamine-DARPP32 feedback in cAMP	<i>CACNA1D, CREB1, GNAS, PPP1R1B</i>	$3.36 \times 10^{-5}$
Serotonin receptor	<i>GNAS, HTR1A, SLC18A1</i>	$1.78 \times 10^{-5}$
Dopamine receptor	<i>SLC18A1, GNAS, PPP1R1B</i>	$9.94 \times 10^{-5}$
Axonal guidance	<i>BDNF, GNAS, GSK3B, IGF1</i>	$1.47 \times 10^{-3}$
Leptin signaling	<i>GNAS, LEP, POMC</i>	$8.5 \times 10^{-5}$
Cardiac hypertrophy	<i>ADRA2A, ADRB1, CACNA1D, CREB1, GNAS, GSK3B, IGF1</i>	$4.65 \times 10^{-9}$
Circadian rhythm signaling	<i>CRY2, CREB1</i>	$6.7 \times 10^{-4}$

The table shows the top canonical pathways and enriched CMMDh genes as identified by IPA (P<0.05). The P-value indicates the likelihood of finding gene enrichment of the given pathway by chance.

AMPK: 5' adenosine monophosphate-activated protein kinase, cAMP: Cyclic Adenosine 3',5'-monophosphate, CMMDh: Cardio-Metabolic Mood Disorders hub genes.

## DISCUSSION

This is the first cross-disorder review that systematically evaluated candidate pleiotropic genes and biological pathways that are likely to be shared with mood disorders, cardiovascular diseases and metabolic disorders. We revealed 24 cardiovascular and metabolic disease genes implicated in either depression, bipolar disorder or both. These genes belong to interrelated signaling pathways important in the hypotheses of both cardio-metabolic diseases and mood disorders: corticotrophin-releasing hormone signaling, AMPK signaling, cAMP-mediated and G-protein coupled receptor signaling, axonal guidance signaling, serotonin and dopamine receptors signaling, dopamine-DARPP32 Feedback in cAMP signaling, leptin signaling and circadian rhythm signaling.

The corticotrophin-releasing hormone (CRH) signaling is one of the top canonical pathways that may underlie the link between CMD-Rs and mood disorders. The CRH signaling pathway comprises of CRH, CRH receptors (CRHR1, CRHR2), and other CRH-related peptides. It is the principal regulator of the hypothalamic–pituitary–adrenal (HPA) axis. There are consistent findings in the literature that support the role of the HPA axis dysregulation in mediating the risk of mood disorders and cardiovascular outcome (121). Our analysis found enriched CMMdh genes in the CRH signaling pathways (*BDNF*, *CREB1*, *GNAS*, *POMC*). Genetic variants of the genes for *BDNF*, *CREB1*, *GNAS*, and *POMC* increased the risk of MDD (89, 96), BPD (44), obesity (27, 81), blood pressure and hypertension (31, 36). These genes could be stress responsive, and their activity could be modulated through the activation of the HPA-axis. In animal studies, the expression of *BDNF* (122) and *CREB1* (123) genes was dysregulated by chronic stress. It is therefore possible that an interaction of *BDNF*, *CREB1*, *GNAS*, and *POMC* genes with exposure to chronic stress or traumatic life events increase the risk of cardio-

metabolic and mood disorders either simultaneously, or through mediating factors. The CRH signaling pathway is an important mediator of stress responses (124). Following an exposure to stress, the hypothalamus releases CRH, stimulating secretion of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland. ACTH in turn stimulates the adrenal gland to produce glucocorticoids (principally cortisol). Cortisol will then act on several organs including the brain through its receptors (124). In acute conditions, the production of cortisol helps the body to fight pathogens (stress) and alleviate inflammation. However, when stressors are long lasting (chronic) they can cause cortisol receptor resistance and failure of the HPA-axis negative feedback mechanism. This increases the duration and chronicity of inflammation, and a failure to down-regulate the inflammatory response. Ultimately, failure in the HPA-axis processes may cause dysfunctions in the brain and body, causing both somatic and brain disorders. Hence, it is imperative to recognize the sources of the stress, especially chronic stress. Stress can either originate from the external environment as chronic extrinsic stress (CES) or within the internal body system as chronic intrinsic stress (CIS). Both CES and CIS can influence the CRH pathway genes mainly through gene expression and DNA methylation mechanisms (125). In relation to stress, there are two possibilities to explain mood disorders to cardio-metabolic diseases association. The first is that the human body system may consider the CMD-Rs as CIS and then dysregulate the HPA-axis through the CRH signaling pathway. Another possibility is that CES and/or CIS interact with the CRH signaling genes to cause both CMD-Rs and mood disorders. In either of the conditions, the CRH signaling genes interacts with the stressors to cause a dysfunction in the HPA-axis.

The second main canonical pathway was the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway. This pathway regulates the intercellular energy balance. It inhibits or induces ATP consuming and generating pathways as needed. This pathway is especially important for nerve cells, as they need more energy with small energy reserves (126). Abnormalities in the pathway can disturb normal brain functioning. In animal studies, Zhu et al., 2014 showed chronically stressed mice developed symptoms related to mood and metabolic abnormalities, such as significant weight gain, heightened anxiety, and depressive like behavior. They also reported decreased levels of phosphorylated AMP-activated protein kinase  $\alpha$  (AMPK $\alpha$ ), confirming the involvement of the AMPK pathway and its regulatory genes in metabolic disorders and depression (127). Recent studies also reported the activation of the AMPK pathway in rat hippocampus after ketamine treatment exerting rapid antidepressant effect (128). Major contributing CMMIDh genes enriched in the AMPK pathway were *ADRA2A*, *ADRB1*, *LEP*, *CREB1* and *GNAS* genes. Variations in one or more of these genes can influence the activity of the AMPK pathway, subsequently impairing energy homeostasis in the brain and possibly in other cells (126). This can later cause energy shortage for the brain and somatic cells. Since brain cells are the most vulnerable units that require substantial amount of energy supply, any energy shortage would severely affect first the brain. Symptoms of mood change such as depressive behavior can be observed during this process. Moreover, AMP activation, for instance during stress, could induce insulin resistance promoting metabolic syndrome i.e. obesity, diabetes and cardiovascular diseases (129, 130). Hence, it is very likely that inappropriate activity of the AMPK pathway can imbalance the energy needs of the cells and be a cause to mood disorders and cardio-metabolic diseases.

Axonal guidance signaling was also among the top overrepresented canonical pathways. Axonal guidance signaling is related to neuronal connections formed by the extension of axons, which migrate to reach their synaptic targets. Axon guidance is an important step in neural development. It allows growing axons to stretch and reach the next target axon to form the complex neuronal networks in the brain and throughout the body. The patterns of connection between nerves depend on the regulated action of guidance cues and their neuronal receptors that are themselves encoded by axonal guidance coding genes. Activation of specific signaling pathways can promote attraction or repulsion and affect the rate of axon extension. One important observation in the axonal guidance pathway is the role of calcium and voltage-dependent calcium channels. The pathway is regulated by the entrance of calcium through the plasma membrane and release from intracellular calcium store. Calcium has been implicated in controlling axon outgrowth (131). CMMDh genes overrepresented in the axonal guidance-signaling pathway include the *BDNF*, *GNAS*, *GSK3B*, and *IGF1* genes. Mutant axonal guidance genes followed by abnormal axon guidance and connectivity could cause a disorder primarily in the brain and subsequently to the peripheral organs (132).

Other strong candidate mechanisms underlying mood disorders and cardio-metabolic diseases are the serotonin and dopamine receptors signaling pathways. The serotonin pathway is mainly regulated by serotonin and its receptors known as 5-hydroxytryptamine (5-HT) receptors. Serotonin is a monoamine neurotransmitter synthesized in the central nervous system and its signaling modulates several physiological processes including regulation of appetite, mood and sleep, body temperature and metabolism. The *SLC18A1*, *HTR1A* and *GNAS* gene were among the CMMDh genes involved in the serotonin receptor-signaling pathway. The *SLC18A1* gene encodes for the vesicular monoamine transporter that transports for monoamines. Its proper



function is essential to the correct activity of the monoaminergic systems that have been implicated in several human neuropsychiatric disorders (133). The *HTR1A* gene encodes a receptor for serotonin, and it belongs to the 5-hydroxytryptamine receptor subfamily. Dysregulation of serotonergic neurotransmission has been suggested to contribute for the pathogenesis of mood disorders (60, 61) and it is implicated in the action of selective serotonin reuptake inhibitors (63-65). Moreover, animal studies have consistently demonstrated the influence of the serotonin pathway on both mood disorders and cardio-metabolic disorders. Ohta et al., 2011 have previously revealed as there is a converge in insulin and serotonin producing cells that can lead to metabolic diseases (diabetes) and mood disorders (134). The products of the insulin-producing cells (beta-islet cells) are involved to express the genes that synthesize serotonin, and serotonin also plays a role in the synthesis of insulin in the beta-islet cells (134).

The dopamine receptors pathway, centrally regulated by dopamine, also appears to underlie the relationship between mood disorders and cardio-metabolic diseases. Dopamine serves as a chemical messenger in the nervous system and its signaling plays important roles in processes: emotion, positive reinforcement, motivation, movement, and in the periphery as a modulator of renal, cardiovascular and the endocrine systems (135). The *SLC18A1* and *GNAS* genes are among the CMMDh genes that belong to this pathway. The dopamine-signaling pathway further induces the dopamine-DARPP32 Feedback in cAMP signaling. The central regulator of this pathway is the *PPP1R1B* gene that encodes a bifunctional signal transduction molecule called the dopamine and cAMP-regulated neuronal phosphoprotein (DARPP-32). Other important CMMDh genes in this pathway include *CACNA1D*, *CREB1*, and *GNAS*. The *CACNA1D* gene encodes the alpha-1D subunit of the calcium channels that mediates the entry of calcium ions

into excitable cells. Calcium channel proteins are involved in a variety of calcium-dependent processes, including hormone or neurotransmitter release, and gene expression (136).

We also performed a gene network analysis of the CMMDh genes to the mood disorders and cardio-metabolic diseases. Based on the network analysis, the CMMDh genes were centrally involved in the link between mood disorders and the cardio-metabolic diseases. For instance, *ADRB1* and *ADRA2A* genes linked the four most common cardio-metabolic diseases (coronary diseases, hypertension, diabetes, obesity) with BPD and depressive disorder. The *CACNB2* and *CACNAID* genes have shown network with coronary diseases, hypertension, diabetes, BPD and depression. Similarly, the other CMMDh genes acted as a hub between at least one of the cardio-metabolic disorders and BPD and/or depression (figure 2).

Overall, genes that encode for molecules involved in HPA-axis activity, circadian rhythm, inflammation, neurotransmission, metabolism and energy balance were found to play a central role to link mood disorders with cardio-metabolic diseases. It is also worth noting the impact of the environment, such as the CES and CIS, on the genes associated with these diseases. First, it could be that cardio-metabolic disorders and associated risk factors alter the intrinsic body environment, and this change interacts with the genes to cause mood disorders or influence treatment response in patients with mood disorders. Second, a biochemical change following the mutation of genes could result in both disease conditions simultaneously.

## **IMPLICATIONS OF THE REVIEW FINDINGS**

Knowledge of genes and molecular pathways that are shared between mood disorders and cardio-metabolic disorders could have several important implications for future research and clinical practice. It is expected that increasing sample size, and consequently increasing power,

will identify many more of these variants in the near future. Here we identify four implications of our findings.

Firstly, the identification of shared molecular pathways implicated in disease susceptibility supports a growing evidence base for cross-diagnostic treatment paradigms. Shared molecular pathways could help explain recent findings of reduced cardiovascular mortality (137), or improved diabetic control (138), in MDD patients treated with SSRIs. Secondly, further exploration of overlapping molecular pathophysiology has the potential to unveil novel targets for drug development, and may give clues for the re-purposing of existing medications.

Thirdly, cardio-metabolic disorders are associated with an increased risk of poor response to standard treatments in mood disorders (139, 140). Genetic profiling for cardio-metabolic risk and stratified diagnosis of patients may help to classify treatment responders and treat them accordingly, thereby reducing the costs of ineffective exposure to medicines for the individuals and for the society. Early identification of at-risk individuals would also guide practitioner's treatment recommendations, which may involve alternative somatic (e.g. electroconvulsive therapy, repetitive Transcranial Magnetic Stimulation, ketamine) or specific psychological therapies as first- or second line treatments.

Fourthly, studying the mechanisms of pleiotropic genes and shared pathways of mood disorders and somatic diseases could help untangle the clinical and genetic heterogeneity that characterizes these illnesses. It is possible that a "cardio-metabolic" endophenotype exists among mood disorders patients that may be identifiable through genetic profiling or analysis of blood protein biomarkers. Preliminary evidence for such a phenotype, approximating the concept of "atypical depression" characterized by increased appetite, weight gain, and increased need for sleep, is

emerging(141, 142). Working towards personalized care that allows for precise diagnostic, treatment and prevention strategies, research could then focus on genetically stratified patient cohorts instead of the very diverse patient pool currently diagnosed with MDD or BPD. There is a growing consensus that such stratification approaches have the potential to substantially improve the quality of mental health research and mental healthcare over the coming decades (143).

Our review has limitations. Perhaps the most fundamental limitation was that almost all of the reviewed studies were performed in a univariate manner (single diseases approach). Secondly, the review included studies that reported positively associated genes, and neither negative findings nor inconsistent evidences were assessed. Thirdly, only meta-GWA studies were reviewed for the CMD-Rs. Hence, our review should be viewed as complementary to future mood disorders to cardio-metabolic diseases gene investigation, providing an initial thorough summary of potential pleiotropic genes.

## **CONCLUSION**

Our review revealed potential pleiotropic genes and biological pathways that are likely to be shared between mood disorders and cardio-metabolic diseases. While our review provides some insight into common mechanisms and the role of pleiotropic genes, in-depth understanding of how these genes (and possibly others) mediate the association between mood disorders and cardio-metabolic diseases requires future comprehensive cross-disorder research in large-scale genetic studies. This will enable us to better understand why patients suffer from multiple diseases at a time, and how multi-morbidities influence pharmacological treatment response to diseases.

## **CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest.

## **ACKNOWLEDGMENTS**

The Adelaide Graduate Centre supported this work. Azmeraw T. Amare was a receipt of a postgraduate study scholarship, Adelaide Scholarship International (ASI), from the University of Adelaide.

## REFERENCE

1. Murray CJL, Barber RM, Foreman KJ, Ozgoren AA, Abd-Allah F, Abera SF, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition. *The Lancet*. 2015;386:2145-91.
2. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet*. 2013;382:1575-86.
3. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. *The Lancet*. 2012;380:37-43.
4. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Roux AVD, et al. Examining a Bidirectional Association Between Depressive Symptoms and Diabetes. *JAMA : the journal of the American Medical Association*. 2008;299:2751-9.
5. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: Relationship between illnesses of the endocrine/metabolic system and treatment outcome. *Bipolar Disorders*. 2010;12:404-13.
6. Zelinski EL, Deibel SH, McDonald RJ. The trouble with circadian clock dysfunction: multiple deleterious effects on the brain and body. *Neuroscience and biobehavioral reviews*. 2014;40:80-101.
7. Rosmond R, Björntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. *Journal of internal medicine*. 2000;247:188-97.

8. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska a, Ufnal M, Zera T. Brain and cardiovascular diseases: Common neurogenic background of cardiovascular, metabolic and inflammatory diseases. *Journal of Physiology and Pharmacology*. 2010;61:509-21.
9. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review and meta-analysis. *American Journal of Psychiatry*. 2000;157:1552-62.
10. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *The Lancet*. 2009;373:234-9.
11. McGuffin P, Rijdsdijk F, Andrew M, Sham P, Katz R, Cardno a. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. *Archives of General Psychiatry*. 2003;60:497-502.
12. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. *The New England journal of medicine*. 1994;330:1041-6.
13. Almgren P, Lehtovirta M, Isomaa B, Sarelin L, Taskinen MR, Lyssenko V, et al. Heritability and familiarity of type 2 diabetes and related quantitative traits in the Botnia Study. *Diabetologia*. 2011;54:2811-9.
14. Poulsen P, Ohm Kyvik K, Vaag a, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance - A population-based twin study. *Diabetologia*. 1999;42:139-45.
15. van Rijn MJE, Schut AFC, Aulchenko YS, Deinum J, Sayed-Tabatabaei Fa, Yazdanpanah M, et al. Heritability of blood pressure traits and the genetic contribution to blood

pressure variance explained by four blood-pressure-related genes. *Journal of hypertension*. 2007;25:565-70.

16. Willyard C. Heritability: The family roots of obesity. *Nature*. 2014;508:S58-60.

17. Knoblauch H, Busjahn A, Munter S, Nagy Z, Faulhaber H-D, Schuster H, et al. Heritability Analysis of Lipids and Three Gene Loci in Twins Link the Macrophage Scavenger Receptor to HDL Cholesterol Concentrations. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1997;17:2054-60.

18. Scherrer JF, Xian H, Bucholz KK, Eisen Sa, Lyons MJ, Goldberg J, et al. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. *Psychosom Med*. 2003;65:548-57.

19. López-León S, Aulchenko YS, Tiemeier H, Oostra BA, van Duijn CM, Janssens ACJW. Shared genetic factors in the co-occurrence of symptoms of depression and cardiovascular risk factors. *Journal of Affective Disorders*. 2010;122(3):247-52.

20. Afari N, Noonan C, Goldberg J, Roy-Byrne P, Schur E, Golnari G, et al. Depression and obesity: Do shared genes explain the relationship? *Depression and Anxiety*. 2010;27:799-806.

21. Flint J, Kendler KS. The genetics of major depression. *Neuron*. 2014;81:484-503.

22. Consortium C. Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature*. 2015;523:588.

23. Psychiatric GCBWDWG. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet*. 2011;43(10):977-83.

24. Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nature genetics*. 2015;47:1121-30.



25. Dupuis JJ, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010;42:105-16.
26. Lu X, Wang L, Lin X, Huang J, Charles gu C, He M, et al. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. *Human Molecular Genetics.* 2015;24:865-74.
27. Locke aE, Kahali B, Berndt SI, Justice aE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature.* 2015;518:197-206.
28. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. *Nature genetics.* 2013;45:1274-83.
29. Scott Ra, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan Ja, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nature genetics.* 2012;44:991-1005.
30. Manning AK, Hivert M-F, Scott Ra, Grimsby JL, Bouatia-Naji N, Chen H, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nature genetics.* 2012;44:659-69.
31. Studies ICfBPG-WA, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature.* 2011;478:103-9.
32. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic acids research.* 2014;42:D1001-6.

33. Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, et al. Abundant pleiotropy in human complex diseases and traits. *American Journal of Human Genetics*. 2011;89:607-18.
34. Westra H-J, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nature Genetics*. 2013;45:1238-43.
35. Grundberg E, Small KS, Hedman ÅK, Nica AC, Buil A, Keildson S, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nature Genetics*. 2012;44:1084-9.
36. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nature genetics*. 2011;43:1005-11.
37. Lewis SJ, Lawlor Da, Davey Smith G, Araya R, Timpson N, Day INM, et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. *Molecular psychiatry*. 2006;11:352-60.
38. Peerbooms OL, van Os J, Drukker M, Kenis G, Hoogveld L, Group MiP, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? *Brain, behavior, and immunity*. 2011;25(8):1530-43.
39. Lok a, Bockting CLH, Koeter MWJ, Snieder H, Assies J, Mocking RJT, et al. Interaction between the MTHFR C677T polymorphism and traumatic childhood events predicts depression. *Translational psychiatry*. 2013;3:e288.

40. Ament Sa, Szelinger S, Glusman G, Ashworth J, Hou L, Akula N, et al. Rare variants in neuronal excitability genes influence risk for bipolar disorder. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112:3576-81.
41. McCarthy MJ, Le Roux MJ, Wei H, Beesley S, Kelsoe JR, Welsh DK. Calcium channel genes associated with bipolar disorder modulate lithium's amplification of circadian rhythms. *Neuropharmacology*. 2016;101:439-48.
42. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. *Nature genetics*. 2009;41:677-87.
43. Smoller JW. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. *The Lancet*. 2013;381:1371-9.
44. McDonald ML, MacMullen C, Liu DJ, Leal SM, Davis RL. Genetic association of cyclic AMP signaling genes with bipolar disorder. *Translational psychiatry*. 2012;2:e169.
45. Klenke S, Siffert W. SNPs in genes encoding G proteins in pharmacogenetics. *Pharmacogenomics*. 2011;12:633-54.
46. Zill P, Baghai TC, Engel R, Zwanzger P, Schüle C, Minov C, et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*. 2003;120B:85-9.
47. Otsuki K, Uchida S, Wakabayashi Y, Matsubara T, Hobara T, Funato H, et al. Aberrant REST-mediated transcriptional regulation in major depressive disorder. *Journal of Psychiatric Research*. 2010;44:378-84.
48. Goswami DB, May WL, Stockmeier Ca, Austin MC. Transcriptional expression of serotonergic regulators in laser-captured microdissected dorsal raphe neurons of subjects with

major depressive disorder: Sex-specific differences. *Journal of Neurochemistry*. 2010;112:397-409.

49. Hara K, Fujita H, Johnson Ta, Yamauchi T, Yasuda K, Horikoshi M, et al. Genome-wide association study identifies three novel loci for type 2 diabetes. *Human Molecular Genetics*. 2014;23:239-46.

50. Kloiber S, Ripke S, Kohli Ma, Reppermund S, Salyakina D, Uher R, et al. Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. *European Neuropsychopharmacology*. 2013;23:653-62.

51. Eikelis N, Esler M, Barton D, Dawood T, Wiesner G, Lambert G. Reduced brain leptin in patients with major depressive disorder and in suicide victims. *Molecular psychiatry*. 2006;11:800-1.

52. Haefner S, Baghai TC, Schule C, Eser D, Spraul M, Zill P, et al. Impact of gene-gender effects of adrenergic polymorphisms on hypothalamic-pituitary-adrenal axis activity in depressed patients. *Neuropsychobiology*. 2008;58:154-62.

53. Kato M, Serretti a, Nonen S, Takekita Y, Wakeno M, Azuma J, et al. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. *Translational psychiatry*. 2015;5:e513.

54. Wakeno M, Kato M, Okugawa G, Fukuda T, Hosoi Y, Takekita Y, et al. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. *Journal of clinical psychopharmacology*. 2008;28:518-24.

55. Perroud N, Aitchison KJ, Uher R, Smith R, Huezo-Diaz P, Marusic A, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP

project. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology. 2009;34:2517-28.

56. Cuffi ML, Artells R, Navarro a, Ciruela F, Carbonell L. Regulation of  $\alpha_2$ -adrenoceptor gene expression by chronic lithium treatment in rat brain. *Methods and findings in experimental and clinical pharmacology*. 2010;32:721-5.

57. Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nature genetics*. 2014;46:234-44.

58. Winham SJ, Cuellar-Barboza AB, Oliveros A, McElroy SL, Crow S, Colby C, et al. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. *Molecular psychiatry*. 2014;19:1010-6.

59. Zheng J-S, Arnett DK, Lee Y-C, Shen J, Parnell LD, Smith CE, et al. Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits. *PloS one*. 2013;8:e77442.

60. Haenisch B, Linsel K, Brüß M, Gilsbach R, Propping P, Nöthen MM, et al. Association of major depression with rare functional variants in norepinephrine transporter and serotonin1A receptor genes. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*. 2009;150:1013-6.

61. Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, Umene-Nakano W, et al. The serotonin 1A receptor gene confer susceptibility to mood disorders: Results from an extended meta-analysis of patients with major depression and bipolar disorder. *European Archives of Psychiatry and Clinical Neuroscience*. 2013;263:105-18.

62. López-Figueroa AL, Norton CS, López-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. *Biological Psychiatry*. 2004;55(3):225-33.
63. Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. Serotonin receptor 1A -1019C/G variant: Impact on antidepressant pharmacoresponse in melancholic depression? *Neuroscience Letters*. 2008;436:111-5.
64. Serretti a, Artioli P, Lorenzi C, Pirovano a, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. *Int J Neuropsychopharmacol*. 2004;7:453-60.
65. Arias B, Catalán R, Gastó C, Gutiérrez B, Fañanás L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. *Journal of psychopharmacology (Oxford, England)*. 2005;19:166-72.
66. Carrard A, Salzman A, Malafosse A, Karege F. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. *J Affect Disord*. 2011;132(3):450-3.
67. Soria V, Martínez-Amorós E, Escaramís G, Valero J, Pérez-Egea R, García C, et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2010;35:1279-89.

68. Geoffroy PA, Lajnef M, Bellivier F, Jamain S, Gard S, Kahn J-P, et al. Genetic association study of circadian genes with seasonal pattern in bipolar disorders. *Scientific reports*. 2015;5:10232.
69. Go MJ, Hwang J-Y, Kim YJ, Hee Oh J, Kim Y-J, Heon Kwak S, et al. New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population. *Journal of human genetics*. 2013;58:362-5.
70. Chambers JC, Weihua Z, Zabaneh D, Sehmi J, Jain P, McCarthy MI, et al. Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians. *Diabetes*. 2009;58:2703-8.
71. Bouatia-Naji N, Bonnefond a, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. *NatGenet*. 2009;41:89-94.
72. Voight BF, Scott LJ, Steinthorsdottir V, Morris aDP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet*. 2010;42:579-89.
73. Gałecka E, Szemraj J, Florkowski A, Gałecki P, Bieńkiewicz M, Karbownik-Lewińska M, et al. Single nucleotide polymorphisms and mRNA expression for melatonin MT2 receptor in depression. *Psychiatry Research*. 2011;189:472-4.
74. Kopczak A, Stalla GK, Uhr M, Lucae S, Hennings J, Ising M, et al. IGF-I in major depression and antidepressant treatment response. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. 2015;25:864-72.

75. Mitschelen M, Yan H, Farley JA, Warrington JP, Han S, Hereñú CB, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. *Neuroscience*. 2011;185:50-60.
76. Pereira ACP, McQuillin A, Puri V, Anjorin A, Bass N, Kandaswamy R, et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*. 2011;156:177-87.
77. Squassina A, Costa M, Congiu D, Manchia M, Angius A, Deiana V, et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. *Pharmacological Research*. 2013;73:1-7.
78. Berndt SI, Gustafsson S, Mägi R, Ganna A, Wheeler E, Feitosa MF, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. *Nature genetics*. 2013;45:501-12.
79. Samaan Z, Anand SS, Anand S, Zhang X, Desai D, Rivera M, et al. The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. *Molecular psychiatry*. 2013;18:1281-6.
80. Rivera M, Cohen-Woods S, Kapur K, Breen G, Ng M, Butler A, et al. Depressive disorder moderates the effect of the FTO gene on body mass index. *Molecular Psychiatry*. 2011;17:604-11.
81. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson aU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet*. 2010;42:937-48.



82. Graff M, Ngwa JS, Workalemahu T, Homuth G, Schipf S, Teumer A, et al. Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course. *Human Molecular Genetics*. 2013;22:3597-607.
83. Chang HS, Won ES, Lee HY, Ham BJ, Kim YG, Lee MS. The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events. *Journal of Neural Transmission*. 2015;122:59-68.
84. Wen W, Zheng W, Okada Y, Takeuchi F, Tabara Y, Hwang J-Y, et al. Meta-analysis of genome-wide association studies in East Asian-ancestry populations identifies four new loci for body mass index. *Human molecular genetics*. 2014;23:5492-504.
85. Finseth PI, S nderby IE, Djurovic S, Agartz I, Malt UF, Melle I, et al. Association analysis between suicidal behaviour and candidate genes of bipolar disorder and schizophrenia. *Journal of Affective Disorders*. 2014;163:110-4.
86. Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y. Toll-like receptors in the depressed and suicide brain. *Journal of Psychiatric Research*. 2014;53:62-8.
87. Hung YY, Kang HY, Huang KW, Huang TL. Association between toll-like receptors expression and major depressive disorder. *Psychiatry Res*. 2014;220:283-6.
88. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadóttir A, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nature genetics*. 2009;41:18-24.
89. Zhang K, Yang C, Xu Y, Sun N, Yang H, Liu J, et al. Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. *Journal of neural transmission (Vienna, Austria : 1996)*. 2010;117:393-401.

90. Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*. 2005;139B:51-3.
91. Sarchiapone M, Carli V, Roy A, Iacoviello L, Cuomo C, Latella MC, et al. Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. *Neuropsychobiology*. 2008;57:139-45.
92. Kim B, Kim CY, Hong JP, Kim SY, Lee C, Joo YH. Brain-derived neurotrophic factor Val/Met polymorphism and bipolar disorder: Association of the met allele with suicidal behavior of bipolar patients. *Neuropsychobiology*. 2008;58:97-103.
93. El-Hage W, Vourc'h P, Gaillard P, Léger J, Belzung C, Ibarguen-Vargas Y, et al. The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients. *Psychopharmacology*. 2014;232:575-81.
94. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2010;34:645-51.
95. Hong W, Fan J, Yuan C, Zhang C, Hu Y, Peng D, et al. Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression. *Neuroreport*. 2014;25:753-5.
96. Zubenko GS, Hughes HB, Stiffler JS, Brechbiel A, Zubenko WN, Maher BS, et al. Sequence variations in CREB1 cosegregate with depressive disorders in women. *Molecular psychiatry*. 2003;8:611-8.

97. Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. *Journal of Affective Disorders*. 2011;128:56-63.
98. Murphy Jr. GM, Sarginson JE, Ryan HS, O'Hara R, Schatzberg aF, Lazzeroni LC. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. *Pharmacogenet Genomics*. 2013;23:301-13.
99. Li M, Luo X-j, Rietschel M, Lewis CM, Mattheisen M, Müller-Myhsok B, et al. Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. *Molecular psychiatry*. 2014;19:452-61.
100. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G. Lithium response and genetic variation in the CREB family of genes. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*. 2008;147:500-4.
101. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet*. 2009;41:47-55.
102. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nature genetics*. 2008;40:161-9.
103. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nature genetics*. 2009;41:56-65.

104. Cichon S, Mühleisen TW, Degenhardt Fa, Mattheisen M, Miró X, Strohmaier J, et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. *American Journal of Human Genetics*. 2011;88:372-81.
105. Schultz CC, Mühleisen TW, Nenadic I, Koch K, Wagner G, Schachtzabel C, et al. Common variation in NCAN, a risk factor for bipolar disorder and schizophrenia, influences local cortical folding in schizophrenia. *Psychological medicine*. 2014;44:811-20.
106. Diniz BS, Talib LL, Joaquim HPG, de Paula VRJ, Gattaz WF, Forlenza OV. Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry*. 2011;12:216-22.
107. Saus E, Soria V, Escaramís G, Crespo JM, Valero J, Gutiérrez-Zotes a, et al. A haplotype of glycogen synthase kinase 3 $\beta$  is associated with early onset of unipolar major depression. *Genes, Brain and Behavior*. 2010;9:799-807.
108. Lachman HM, Pedrosa E, Petruolo Oa, Cockerham M, Papolos A, Novak T, et al. Increase in GSK3beta gene copy number variation in bipolar disorder. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*. 2007;144B:259-65.
109. Luykx JJ, Boks MP, Terwindt AP, Bakker S, Kahn RS, Ophoff RA. The involvement of GSK3beta in bipolar disorder: integrating evidence from multiple types of genetic studies. *Eur Neuropsychopharmacol*. 2010;20(6):357-68.
110. Mitjans M, Arias B, Jiménez E, Goikolea JM, Sáiz Pa, García-Portilla MP, et al. Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium

Response: Association With IMPA2, INPP1, and GSK3B Genes. *Journal of clinical psychopharmacology*. 2015;35:600-4.

111. Iwahashi K, Nishizawa D, Narita S, Numajiri M, Murayama O, Yoshihara E, et al. Haplotype analysis of GSK-3 $\beta$  gene polymorphisms in bipolar disorder lithium responders and nonresponders. *Clinical neuropharmacology*. 2014;37:108-10.

112. Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I, Arellano-Campos O, et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. *Journal of medical genetics*. 2013;50:298-308.

113. Ko A, Cantor RM, Weissglas-Volkov D, Nikkola E, Reddy PMVL, Sinsheimer JS, et al. Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. *Nature communications*. 2014;5:3983.

114. Kooner JS, Chambers JC, Aguilar-Salinas Ca, Hinds Da, Hyde CL, Warnes GR, et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nature genetics*. 2008;40:149-51.

115. Lohoff FW, Dahl JP, Ferraro TN, Arnold SE, Gallinat J, Sander T, et al. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2006;31:2739-47.

116. Ishikawa M, Mizukami K, Iwakiri M, Asada T. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2007;31:1177-81.

117. Kunii Y, Hyde TM, Ye T, Li C, Kolachana B, Dickinson D, et al. Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. *Molecular Psychiatry*. 2014;19:192-9.
118. Coram Ma, Duan Q, Hoffmann TJ, Thornton T, Knowles JW, Johnson Na, et al. Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations. *American Journal of Human Genetics*. 2013;92:904-16.
119. Kim YJ, Go MJ, Hu C, Hong CB, Kim YK, Lee JY, et al. Large-scale genome-wide association studies in east Asians identify new genetic loci influencing metabolic traits. *Nature Genetics*. 2011;43:990-5.
120. Yen Y-C, Rebok GW, Gallo JJ, Yang M-J, Lung F-W, Shih C-H. ApoE4 allele is associated with late-life depression: a population-based study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2007;15:858-68.
121. Jokinen J, Nordstrom P. HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients. *J Affect Disord*. 2009;116(1-2):88-92.
122. Smith MA, Makino S, Kim SY, Kvetnansky R. Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. *Endocrinology*. 1995;136(9):3743-50.
123. Grønli J, Bramham C, Murison R, Kanhema T, Fiske E, Bjorvatn B, et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper. *Pharmacology Biochemistry and Behavior*. 2006;85:842-9.

124. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. *CNS Neurol Disord Drug Targets*. 2006;5(4):453-79.
125. Mychasiuk R, Muhammad A, Kolb B. Chronic stress induces persistent changes in global DNA methylation and gene expression in the medial prefrontal cortex, orbitofrontal cortex, and hippocampus. *Neuroscience*.
126. Ronnett GV, Aja S. AMP-activated protein kinase in the brain. *International journal of obesity (2005)*. 2008;32 Suppl 4:S42-8.
127. Zhu S, Wang J, Zhang Y, Li V, Kong J, He J, et al. Unpredictable chronic mild stress induces anxiety and depression-like behaviors and inactivates AMP-activated protein kinase in mice. *Brain Research*. 2014;1576:81-90.
128. Xu SX, Zhou ZQ, Li XM, Ji MH, Zhang GF, Yang JJ. The activation of adenosine monophosphate-activated protein kinase in rat hippocampus contributes to the rapid antidepressant effect of ketamine. *Behav Brain Res*. 2013;253:305-9.
129. Steinberg GR, Kemp BE. AMPK in Health and Disease. *Physiol Rev*. 2009;89(3):1025-78.
130. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. *Trends Mol Med*. 2008;14(12):539-49.
131. Sutherland DJ, Pujic Z, Goodhill GJ. Calcium signaling in axon guidance. *Trends Neurosci*. 2014;37(8):424-32.
132. Sasaki T, Oga T, Nakagaki K, Sakai K, Sumida K, Hoshino K, et al. Developmental expression profiles of axon guidance signaling and the immune system in the marmoset cortex:

potential molecular mechanisms of pruning of dendritic spines during primate synapse formation in late infancy and prepuberty (I). *Biochem Biophys Res Commun*. 2014;444(3):302-6.

133. Peter D, Finn JP, Klisak I, Liu Y, Kojis T, Heinzmann C, et al. Chromosomal localization of the human vesicular amine transporter genes. *Genomics*. 1993;18:720-3.

134. Ohta Y, Kosaka Y, Kishimoto N, Wang J, Smith SB, Honig G, et al. Convergence of the insulin and serotonin programs in the pancreatic beta-cell. *Diabetes*. 2011;60(12):3208-16.

135. Gordan R, Gwathmey JK, Xie LH. Autonomic and endocrine control of cardiovascular function. *World journal of cardiology*. 2015;7(4):204-14.

136. The Reference Sequence (RefSeq) Database, (2012).

137. Acharya T, Acharya S, Tringali S, Huang J. Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. *Pharmacotherapy*. 2013;33(10):1053-61.

138. Brieler JA, Lustman PJ, Scherrer JF, Salas J, Schneider FD. Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression. *Fam Pract*. 2016;33(1):30-6.

139. Woo YS, Seo HJ, McIntyre RS, Bahk WM. Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review. *Int J Mol Sci*. 2016;17(1).

140. Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, et al. Insulin resistance and outcome in bipolar disorder. *Br J Psychiatry*. 2015;206(1):52-7.

141. Milaneschi Y, Lamers F, Bot M, Drent ML, Penninx BW. Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. *Biol Psychiatry*. 2015.



142. Lamers F, Beekman AT, van Hemert AM, Schoevers RA, Penninx BW. Six-year longitudinal course and outcomes of subtypes of depression. *Br J Psychiatry*. 2016;208(1):62-8.
143. Schumann G, Binder EB, Holte A, de Kloet ER, Oedegaard KJ, Robbins TW, et al. Stratified medicine for mental disorders. *Eur Neuropsychopharmacol*. 2014;24(1):5-50.